This Dividend Champion Appears 25%-Plus Undervalued: Aflac (AFL)


The market reaction to the COVID-19 pandemic was a swift market crash (about a month long) after the market hits its all-time high on February 19, followed by a slower recovery (about two months).

Exaggerated volatility has been evident in both the crash and the partial recovery that has followed. Altogether, the S&P 500 index is down about 9% since the beginning of the 2020.

As I explained in March, I believe that in the long run, valuations matter. With that in mind, let’s look at the valuation of a particular stock in the Valuation Zone, while remembering that in market and economic conditions like these, every stock investment has a considerable speculative dimension beyond the normal.

The choice this month is Aflac, Inc. (AFL), represented by the ubiquitous duck.

Aflac primarily sells supplemental health and life insurance in the United States and Japan. Overall, the company provides protection to more than 50 million people.

“Supplemental insurance” means that the company pays cash to policyholders when they get sick or injured.

The idea is that financial support for expenses not covered by health insurance allows policyholders to focus on recovery, not financial stress.

Japan accounts for about two-thirds of Aflac’s revenues.

Aflac Life Insurance Japan is the leading provider of medical and cancer insurance in Japan, where it insures 1 in 4 households.

Aflac has received numerous accolades, including Fortune’s 100 best companies to work for (20 consecutive years), World’s Most Ethical Companies (14 years), and Fortune’s World’s Most Admired Companies (19 years).

Disclosure: My wife and I have owned Aflac in our personal Perpetual Dividends Portfolio for several years.

Quality Snapshot and Dividend Record

I recently added Dividend Growth Investing Lesson 20: Quality Snapshots to DTA’s educational series. As explained there, I derive Quality Snapshots from the following sources, which I have come to trust and respect over the years:

• Safety and Financial Strength grades from Value Line
S&P’s Credit rating
Morningstar’s Moat rating, and
Simply Safe Dividends’ Dividend Safety grade.

Aflac’s quality score is attractive except for the no-moat rating from Morningstar.

• Three of the five factors are green “Above Average” or “Excellent” grades. Its dividend grades out as being extremely safe.
• The Value Line Financial Strength grade (A) was upgraded in late 2018.
• Morningstar’s no-moat rating was determined by algorithm, as there is no assigned analyst for the company. I include it for completeness, but there is little meaning to be attached to it.

On the Quality Snapshot scoring system, Aflac gets 18 points, which makes it an acceptable investment-grade company to consider.

Aflac’s yield is 3.2%, which is mid-range. Aflac has a 38-year streak of dividend increases., which makes it a Dividend Champion. The company increased its dividend payout by 3.7% in March, 2020.

As shown here, Aflac’s long-term record of dividend increases is strong.

[Source: Simply Safe Dividends]

Overall, I would describe Aflac as a mid-yield, mid-growth stock.

The Duck in the Valuation Zone

To value a stock, I use four different valuation models, then average them. For more details on my approach, see Dividend Growth Investing Lesson 11: Valuation.

Model 1: FASTGraphs Default Valuation

The first model checks the stock’s current price against FASTGraphs’ basic estimate of its fair value.

FASTGraphs usually uses the historical average P/E ratio of the whole stock market to represent a fair valuation. With a slow-growth company, FASTGraphs picks a lower P/E ratio for reference. In Aflac’s case, that lower P/E is 12.3, which is used to draw the orange fair-price reference line on the following graph. The black line is Aflac’s price.

Using this model, Aflac comes across as quite undervalued.

Formula for Measuring Valuation on FASTGraphs
Valuation Ratio = Actual P/E divided by Reference P/E
Valuation Ratio = 8.1 / 12.3 = 0.66

That valuation ratio suggests that Aflac is 34% undervalued. We use that ratio to calculate a fair price.

Formula for Calculating Fair Price
Actual Price divided by Valuation Ratio = Fair Price
$35 / 0.66 = $53

Model 2: FASTGraphs Normalized Valuation

FASTGraphs offers another fair-value reference line. This one is based on the stock’s own long-term valuation rather than the market as a whole. That is, this model “normalizes” the valuation to the company’s own historical record.

In the following graph, Aflac’s 5-year average P/E ratio (circled) was used to draw the blue fair-value reference line. Aflac’s price is the black line.

This model presents Aflac as less undervalued, because the stock’s 5-year average valuation is lower than the reference used in the first model.

The formulas for the valuation ratio and fair price are the same as above. Applying them, we get:

Valuation ratio: 8.1 / 10.8 = 0.75, or 25% undervalued
Fair price: $35 / 0.75 = $47

Model 3: Morningstar’s Valuation

Morningstar takes a different approach to valuation. They ignore P/E and other valuation ratios.

Instead, they construct a discounted cash flow (DCF) model. Using conservative projections, they discount all of the stock’s estimated future cash flows back to the present to arrive at a fair value estimate. The idea is that a stock’s fair price is equal to the net present value of all of the company’s future cash flows.

Here is Morningstar’s conclusion:

Morningstar also calculates Aflac’s price as far undervalued. Their valuation ratio is 0.73, which leads to a fair price estimate of $48 per share.

The “Q” superscript indicates that this was all done by algorithm (no analyst).

Model 4: Current Yield vs. Historical Yield

The final valuation method is to compare the stock’s current yield to its historical yield.

If a stock is yielding more than its historical average, that suggests that it is a better value than usual, because you are paying less for the stock’s dividends.

Another way to put this is that, with a well-valued stock, you can buy more shares with your money. Because dividends are paid per share, you will get more dividends for your money.

This relative-yield model suggests that Aflac is undervalued.

[Source: Simply Safe Dividends]

Formula for Measuring Valuation by Comparing Yields
Valuation Ratio = 5-Year Average Yield divided by Current Yield
Valuation Ratio = 2.3% / 3.2% = 0.72, or 28% undervalued

When I use this yield-comparison model, I put a floor under the valuation ratio at 0.80, because I think that this model is an indirect way to measure valuation.

Using that floor, Aflac is 20% undervalued. Then applying the same equation for fair price as in the other models, we get a fair price of $35 / 0.80 = $44.

Aflac’s Valuation Summary

Now we average the 4 approaches.

All four models agree that The Duck is undervalued. The average of the four models suggests a fair price of $48, compared to its recent price of $35.

Closing Thoughts

Aflac has an investment-grade Quality Snapshot, very good dividend track record, and a dividend that has been raised for 38 straight years and is rated as extremely safe by Simply Safe Dividends. The stock appears to be very undervalued at the moment.

All things considered, I see Aflac as an attractive dividend growth opportunity, especially selling at the extreme discount that is now available.

This is not a recommendation to buy Aflac Inc. As always, perform your own due diligence. Check the company’s complete dividend record, business model, financial situation, and prospects for the future. Also consider your tolerance for risk and how well the company fits (or does not fit) your long-term investing goals.

— Dave Van Knapp

Urgent Stock Market Warning: Move your money before 2021 [sponsor]
According to a former hedge fund manager with 500,000 followers around the world, the next three months could determine who will become fabulously wealthy in 2021 – and who won’t. It has nothing to do with the COVID-19 crisis. Instead, it’s a huge stock market trend that was already creating millionaires before the pandemic hit. Now, it’s been accelerated. Here’s how to take advantage.